The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study safety and tolerability in patients with type 2 diabetes.

Inclusion Criteria:

• Treated with diet or metformin. Stable glycemic control indicated by no changed treatment within 3 months
• Diabetes Mellitus diagnosis <5 years

Exclusion Criteria:

• Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the investigational product
• Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results